Natick-based Boston Scientific Corp. said a five-year clinical trial has demonstrated the long-term safety of its TAXUS drug-eluting coronary stents.
Boston Scientific said the TAXUS system showed no additional risk for blood clots between years four and five of the clinical trial.
The company announced the trial results at the European Society of Cardiology Congress in Vienna, Austria.
Plummeting stent sales have contributed to Boston Scientific’s precarious financial situation. In recent weeks, the company has restructured debt and announced future lay-offs in its efforts to recover from weakening stent sales and its $27 billion acquisition of Guidant Corp.
